{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:34:32Z","timestamp":1790883272098,"version":"4.1.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T00:00:00Z","timestamp":1729209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T00:00:00Z","timestamp":1729209600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J GEN INTERN MED"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Direct-acting oral anticoagulants (DOACs) are recommended to reduce risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF). However, DOAC dosing inconsistent with FDA-approved product labels is common and associated with poor clinical outcomes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Objectives<\/jats:title>\n            <jats:p>Identify DOAC dosing inconsistent with FDA-approved product labels in ambulatory care patients with NVAF; identify variables associated with dosing lower and higher than label.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Design<\/jats:title>\n            <jats:p>Retrospective analysis using electronic health records from nine US healthcare systems.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patients<\/jats:title>\n            <jats:p>Adults with NVAF receiving DOAC therapy in 2022.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Main Measures<\/jats:title>\n            <jats:p>Rates of label-inconsistent dosing; multivariable regression analysis to identify demographic and clinical variables associated with dosing lower and higher than label.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Key Results<\/jats:title>\n            <jats:p>Among 51,128 NVAF patients (56.1% male, 94.3% White, mean [SD] age 73.5 [10.5] years), 5008 (9.8%) were prescribed label-inconsistent doses of DOACs (6.8% lower and 3.0% higher than label). Age\u2009\u2265\u200975\u00a0years, renal impairment, and hypertension were significantly associated with inconsistent dosing both higher and lower than label. Female sex and higher weight were significantly associated with dosing lower than label, as were heart failure, vascular or liver disease, and bleeding history. Dosing higher than label was significantly associated with male sex, race (African American\/Black), weight\u2009&lt;\u200960\u00a0kg, and use of drugs with potential drug-drug interactions. When prescribed by primary care physicians, DOAC doses were 37% (95% CI, 27\u201349%) more likely to be lower than label and 30% (95% CI, 16\u201346%) more likely to be higher than label than when prescribed by cardiologists or electrophysiologists. Label-inconsistent dosing varied (6.7 to 15.8%) across participating systems.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>DOAC dosing inconsistent with label varied by demographics, clinical characteristics, prescriber specialty, and healthcare system, suggesting a need to monitor and assess dosing decisions in NVAF. Identification of variables associated with dosing inconsistencies may enable targeted interventions to ensure label-consistent dosing in vulnerable populations.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s11606-024-09106-w","type":"journal-article","created":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T17:02:21Z","timestamp":1729270941000},"page":"828-837","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Direct-Acting Oral Anticoagulants and Potential Inconsistencies with FDA-Approved Dosing for Non-Valvular Atrial Fibrillation: A Retrospective Real-World Analysis Across Nine US Healthcare Systems"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-3230-3141","authenticated-orcid":false,"given":"Bonnie","family":"DeLor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon J.","family":"Glover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy J.","family":"Hartman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura L.","family":"Manzey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Ateya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelby","family":"Kelsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wesley R.","family":"Zemrak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaclynne R.","family":"Gowen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Parks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Gust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Medico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ukwen C.","family":"Akpoji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shane","family":"Naylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn W.","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Fakelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Hart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eryne E.","family":"Wiethorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thach","family":"Trinh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William W.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Bowen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Stanton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Duvall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynette T.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the D-DARE Consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Ansara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Child","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard W.","family":"Dettloff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saira Naim","family":"Haqu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saba","family":"Sarsam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Somand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Wadsworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,18]]},"reference":[{"issue":"8","key":"9106_CR1","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/europace\/euy054","volume":"20","author":"J Steffel","year":"2018","unstructured":"Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary. Europace. 2018;20(8):1231-42. https:\/\/doi.org\/10.1093\/europace\/euy054","journal-title":"Europace."},{"issue":"5","key":"9106_CR2","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"G Hindricks","year":"2021","unstructured":"Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstrom-Lundqvist C, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373-498. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa612","journal-title":"Eur Heart J."},{"issue":"1","key":"9106_CR3","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1161\/CIR.0000000000001193","volume":"149","author":"JA Joglar","year":"2024","unstructured":"Joglar JA, Chung MK, Armbruster AL, Benjamin EJ, Chyou JY, Cronin EM, et al. 2023 ACC\/AHA\/ACCP\/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024;149(1):e1-e156. https:\/\/doi.org\/10.1161\/CIR.0000000000001193","journal-title":"Circ."},{"issue":"12","key":"9106_CR4","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-51. https:\/\/doi.org\/10.1056\/NEJMoa0905561","journal-title":"N Engl J Med."},{"issue":"11","key":"9106_CR5","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-92. https:\/\/doi.org\/10.1056\/NEJMoa1107039","journal-title":"N Engl J Med."},{"issue":"10","key":"9106_CR6","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883-91. https:\/\/doi.org\/10.1056\/NEJMoa1009638","journal-title":"N Engl J Med."},{"issue":"22","key":"9106_CR7","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","volume":"369","author":"RP Giugliano","year":"2013","unstructured":"Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093-104. https:\/\/doi.org\/10.1056\/NEJMoa1310907","journal-title":"N Engl J Med."},{"issue":"9921","key":"9106_CR8","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","volume":"383","author":"CT Ruff","year":"2014","unstructured":"Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955-62. https:\/\/doi.org\/10.1016\/S0140-6736(13)62343-0","journal-title":"Lancet."},{"key":"9106_CR9","unstructured":"Chitavi S, Larios H, Braun B, Bland A. Direct oral anticoagulant therapy workgroup: Resources to support Joint Commission Accredited organizations implementation of NPSG.03.05.01. https:\/\/www.jointcommission.org\/standards\/national-patient-safety-goals\/-\/media\/91e55d5d90e34d20b8496b0c39bcc614.ashx. Accessed August 4 2023."},{"key":"9106_CR10","unstructured":"U.S. Department of Health and Human Services, Office of Disease Prevention and Health Promotion. National Action Plan for Adverse Drug Event Prevention.. Section 5. Anticoagulants. 2014. https:\/\/health.gov\/about-odphp\/previous-initiatives\/national-ade-action-plan. Accessed August 4 2023."},{"key":"9106_CR11","unstructured":"Institute for Safe Medication Practices. High-Alert Medication Feature: Anticoagulant Safety Takes Center Stage In 2007. 2007. https:\/\/www.ismp.org\/resources\/high-alert-medication-feature-anticoagulant-safety-takes-center-stage-2007. Accessed August 4 2023."},{"key":"9106_CR12","unstructured":"National Quality Forum. Advancing Anticoagulation Stewardship: A Playbook. 2022. https:\/\/psnet.ahrq.gov\/issue\/advancing-anticoagulation-stewardship-playbook. Accessed August 6 2023."},{"key":"9106_CR13","unstructured":"The Joint Commission. National Patient Safety Goals. https:\/\/www.jointcommission.org\/standards\/national-patient-safety-goals\/-\/media\/b35ba0b4b9754c6dbafdb1f86e152e5c.ashx. Accessed August 4 2023."},{"key":"9106_CR14","unstructured":"Bristol-Myers Squibb Company. Eliquis (apixaban) tablets for oral use. Revised April 2021. https:\/\/packageinserts.bms.com\/pi\/pi_eliquis.pdf. Accessed July 11 2023."},{"key":"9106_CR15","unstructured":"Boehringer Ingelheim Pharmaceuticals Inc. Pradaxa (dabigatran) capsules for oral use. Revised June 2021. https:\/\/content.boehringer-ingelheim.com\/DAM\/c669f898-0c4e-45a2-ba55-af1e011fdf63\/pradaxa%20capsules-us-pi.pdf. Accessed July 11 2023."},{"key":"9106_CR16","unstructured":"Daiichi Sankyo Co. LTD. Savaysa (edoxaban) tablets for oral use. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/206316lbl.pdf. Accessed July 11 2023."},{"key":"9106_CR17","unstructured":"Janssen Pharmaceuticals Inc. Xarelto (rivaroxaban) tablets for oral use. Revised February 2023. https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/XARELTO-pi.p. Accessed July 11 2023."},{"key":"9106_CR18","doi-asserted-by":"publisher","unstructured":"Steinberg BA, Shrader P, Pieper K, Thomas L, Allen LA, Ansell J, et al. Frequency and Outcomes of Reduced Dose Non-Vitamin K Antagonist Anticoagulants: Results From ORBIT-AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II). J Am Heart Assoc. 2018;7(4). https:\/\/doi.org\/10.1161\/JAHA.117.007633","DOI":"10.1161\/JAHA.117.007633"},{"issue":"9","key":"9106_CR19","doi-asserted-by":"publisher","first-page":"e031341","DOI":"10.1136\/bmjopen-2019-031341","volume":"9","author":"LA Garcia Rodriguez","year":"2019","unstructured":"Garcia Rodriguez LA, Martin-Perez M, Vora P, Roberts L, Balabanova Y, Brobert G, et al. Appropriateness of initial dose of non-vitamin K antagonist oral anticoagulants in patients with non-valvular atrial fibrillation in the UK. BMJ Open. 2019;9(9):e031341. https:\/\/doi.org\/10.1136\/bmjopen-2019-031341","journal-title":"BMJ Open."},{"issue":"4","key":"9106_CR20","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.18549\/PharmPract.2019.4.1709","volume":"17","author":"WL Gustafson","year":"2019","unstructured":"Gustafson WL, Saunders J, Vazquez SR, Jones AE, Witt DM. Real-world study of direct oral anticoagulant dosing patterns in patients with atrial fibrillation. Pharm Pract (Granada). 2019;17(4):1709.","journal-title":"Pharm Pract (Granada)."},{"issue":"6","key":"9106_CR21","doi-asserted-by":"publisher","first-page":"e014108","DOI":"10.1161\/JAHA.119.014108","volume":"9","author":"S Sanghai","year":"2020","unstructured":"Sanghai S, Wong C, Wang Z, Clive P, Tran W, Waring M, et al. Rates of Potentially Inappropriate Dosing of Direct-Acting Oral Anticoagulants and Associations With Geriatric Conditions Among Older Patients With Atrial Fibrillation: The SAGE-AF Study. J Am Heart Assoc. 2020;9(6):e014108. https:\/\/doi.org\/10.1161\/JAHA.119.014108","journal-title":"J Am Heart Assoc."},{"issue":"12","key":"9106_CR22","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1016\/j.jacc.2020.07.045","volume":"76","author":"AJ Camm","year":"2020","unstructured":"Camm AJ, Cools F, Virdone S, Bassand JP, Fitzmaurice DA, Arthur Fox KA, et al. Mortality in Patients With Atrial Fibrillation Receiving Nonrecommended Doses of Direct Oral Anticoagulants. J Am Coll Cardiol. 2020;76(12):1425-36. https:\/\/doi.org\/10.1016\/j.jacc.2020.07.045","journal-title":"J Am Coll Cardiol."},{"key":"9106_CR23","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s40780-020-0157-z","volume":"6","author":"M Miyazaki","year":"2020","unstructured":"Miyazaki M, Matsuo K, Uchiyama M, Nakamura Y, Sakamoto Y, Misaki M, et al. Inappropriate direct oral anticoagulant dosing in atrial fibrillation patients is associated with prescriptions for outpatients rather than inpatients: a single-center retrospective cohort study. J Pharm Health Care Sci. 2020;6:2. https:\/\/doi.org\/10.1186\/s40780-020-0157-z","journal-title":"J Pharm Health Care Sci."},{"issue":"11","key":"9106_CR24","doi-asserted-by":"publisher","first-page":"e0259199","DOI":"10.1371\/journal.pone.0259199","volume":"16","author":"Y Qian","year":"2021","unstructured":"Qian Y, Zhang J, Li J, Weng Z. A retrospective study on the evaluation of the appropriateness of oral anticoagulant therapy for patients with atrial fibrillation. PLoS One. 2021;16(11):e0259199. https:\/\/doi.org\/10.1371\/journal.pone.0259199","journal-title":"PLoS One."},{"key":"9106_CR25","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.amjcard.2020.12.062","volume":"144","author":"A Sugrue","year":"2021","unstructured":"Sugrue A, Sanborn D, Amin M, Farwati M, Sridhar H, Ahmed A, et al. Inappropriate Dosing of Direct Oral Anticoagulants in Patients with Atrial Fibrillation. Am J Cardiol. 2021;144:52-9. https:\/\/doi.org\/10.1016\/j.amjcard.2020.12.062","journal-title":"Am J Cardiol."},{"issue":"10","key":"9106_CR26","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1111\/imj.15957","volume":"53","author":"HTK Ko","year":"2022","unstructured":"Ko HTK, Pham J, Anpalahan M. Prevalence and predictors of inappropriate dosing of direct oral anticoagulants. Intern Med J. 2022;53(10):1790-5. https:\/\/doi.org\/10.1111\/imj.15957","journal-title":"Intern Med J."},{"issue":"1","key":"9106_CR27","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1186\/s12913-021-07397-x","volume":"21","author":"AJ Rose","year":"2021","unstructured":"Rose AJ, Lee JS, Berlowitz DR, Liu W, Mitra A, Yu H. Guideline-discordant dosing of direct-acting oral anticoagulants in the veterans health administration. BMC Health Serv Res. 2021;21(1):1351. https:\/\/doi.org\/10.1186\/s12913-021-07397-x","journal-title":"BMC Health Serv Res."},{"key":"9106_CR28","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.thromres.2023.03.007","volume":"231","author":"SFB van der Horst","year":"2023","unstructured":"van der Horst SFB, van Rein N, van Mens TE, Huisman MV, Klok FA. Inappropriate prescriptions of direct oral anticoagulants (DOACs) in hospitalized patients: A narrative review. Thromb Res. 2023;231:135-40. https:\/\/doi.org\/10.1016\/j.thromres.2023.03.007","journal-title":"Thromb Res."},{"issue":"6","key":"9106_CR29","doi-asserted-by":"publisher","first-page":"e2317156","DOI":"10.1001\/jamanetworkopen.2023.17156","volume":"6","author":"JA Rymer","year":"2023","unstructured":"Rymer JA, Chiswell K, Young L, Chiu A, Liu L, Webb L, et al. Analysis of Oral Anticoagulant Dosing and Adherence to Therapy Among Patients With Nonvalvular Atrial Fibrillation. JAMA Netw Open. 2023;6(6):e2317156. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.17156","journal-title":"JAMA Netw Open."},{"issue":"12","key":"9106_CR30","doi-asserted-by":"publisher","first-page":"e010062","DOI":"10.1161\/CIRCOUTCOMES.123.010062","volume":"16","author":"A Sandhu","year":"2023","unstructured":"Sandhu A, Kaltenbach LA, Chiswell K, Shimoga V, Ashur C, Pribish A, et al. Off-Label Dosing of Direct Oral Anticoagulants Among Inpatients with Atrial Fibrillation in the United States. Circ Cardiovasc Qual Outcomes. 2023;16(12):e010062. https:\/\/doi.org\/10.1161\/CIRCOUTCOMES.123.010062","journal-title":"Circ Cardiovasc Qual Outcomes."},{"issue":"4","key":"9106_CR31","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1002\/clc.23586","volume":"44","author":"X Liu","year":"2021","unstructured":"Liu X, Huang M, Ye C, Xiao X, Yan C. Effect of non-recommended doses versus recommended doses of direct oral anticoagulants in atrial fibrillation patients: A meta-analysis. Clin Cardiol. 2021;44(4):472-80. https:\/\/doi.org\/10.1002\/clc.23586","journal-title":"Clin Cardiol."},{"key":"9106_CR32","doi-asserted-by":"publisher","first-page":"724301","DOI":"10.3389\/fcvm.2021.724301","volume":"8","author":"X Wu","year":"2021","unstructured":"Wu X, Hu L, Liu J, Gu Q. Off-Label Underdosing or Overdosing of Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation: A Meta-Analysis. Front Cardiovasc Med. 2021;8:724301. https:\/\/doi.org\/10.3389\/fcvm.2021.724301","journal-title":"Front Cardiovasc Med."},{"issue":"12","key":"9106_CR33","doi-asserted-by":"publisher","first-page":"e007971","DOI":"10.1161\/CIRCOUTCOMES.121.007971","volume":"14","author":"XL Zhang","year":"2021","unstructured":"Zhang XL, Zhang XW, Wang TY, Wang HW, Chen Z, Xu B, et al. Off-Label Under- and Overdosing of Direct Oral Anticoagulants in Patients With Atrial Fibrillation: A Meta-Analysis. Circ Cardiovasc Qual Outcomes. 2021;14(12):e007971. https:\/\/doi.org\/10.1161\/CIRCOUTCOMES.121.007971","journal-title":"Circ Cardiovasc Qual Outcomes."},{"key":"9106_CR34","doi-asserted-by":"publisher","unstructured":"Kido K, Shimizu M, Shiga T, Hashiguchi M. Meta-analysis comparing inappropriately low dose versus standard dose of direct oral anticoagulants in patients with atrial fibrillation. J Am Pharm Assoc (2003). 2022;62(2):487\u201395 e2. https:\/\/doi.org\/10.1016\/j.japh.2021.10.027","DOI":"10.1016\/j.japh.2021.10.027"},{"key":"9106_CR35","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.ijcard.2022.04.062","volume":"362","author":"MQ Pereira","year":"2022","unstructured":"Pereira MQ, David C, Almeida AG, Brito D, Pinto FJ, Caldeira D. Clinical effects of off-label reduced doses of Direct Oral Anticoagulants: A systematic review and meta-analysis. Int J Cardiol. 2022;362:76-82. https:\/\/doi.org\/10.1016\/j.ijcard.2022.04.062","journal-title":"Int J Cardiol."},{"issue":"10","key":"9106_CR36","doi-asserted-by":"publisher","first-page":"e13819","DOI":"10.1111\/eci.13819","volume":"52","author":"C Sang","year":"2022","unstructured":"Sang C, Chen J, Sun J, Lai Y, Liu X, Zhu W. Off-label underdosing of four individual NOACs in patients with nonvalvular atrial fibrillation: A systematic review and meta-analysis of observational studies. Eur J Clin Invest. 2022;52(10):e13819. https:\/\/doi.org\/10.1111\/eci.13819","journal-title":"Eur J Clin Invest."},{"issue":"3","key":"9106_CR37","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1136\/heartjnl-2022-321114","volume":"109","author":"V Caso","year":"2023","unstructured":"Caso V, de Groot JR, Sanmartin Fernandez M, Segura T, Blomstrom-Lundqvist C, Hargroves D, et al. Outcomes and drivers of inappropriate dosing of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation: a systematic review and meta-analysis. Heart. 2023;109(3):178-85. https:\/\/doi.org\/10.1136\/heartjnl-2022-321114","journal-title":"Heart."},{"key":"9106_CR38","doi-asserted-by":"publisher","unstructured":"Joosten LPT, van Maanen R, van den Dries CJ, Rutten FH, Hoes AW, Granger CB, et al. Clinical consequences of off-label reduced dosing of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a systematic review and meta-analysis. Open Heart. 2023;10(1). https:\/\/doi.org\/10.1136\/openhrt-2022-002197","DOI":"10.1136\/openhrt-2022-002197"},{"issue":"1","key":"9106_CR39","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1159\/000525407","volume":"86","author":"MG Mosconi","year":"2023","unstructured":"Mosconi MG, Maraziti G, Paciaroni M, Giustozzi M, Vedovati MC, Bogliari G, et al. Effects of Direct Oral Anticoagulants\u2019 Nonrecommended Dose in Atrial Fibrillation: A Meta-Analysis. Eur Neurol. 2023;86(1):13-24. https:\/\/doi.org\/10.1159\/000525407","journal-title":"Eur Neurol."},{"issue":"1","key":"9106_CR40","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault H. Prediction of Creatinine Clearance from Serum Creatinine. Nephron. 1976;16(1):31-41. https:\/\/doi.org\/10.1159\/000180580","journal-title":"Nephron."},{"issue":"22","key":"9106_CR41","doi-asserted-by":"publisher","first-page":"2864","DOI":"10.1001\/jama.285.22.2864","volume":"285","author":"BF Gage","year":"2001","unstructured":"Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285(22):2864-70. https:\/\/doi.org\/10.1001\/jama.285.22.2864","journal-title":"JAMA."},{"issue":"2","key":"9106_CR42","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1378\/chest.09-1584","volume":"137","author":"GY Lip","year":"2010","unstructured":"Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263-72. https:\/\/doi.org\/10.1378\/chest.09-1584","journal-title":"Chest."},{"issue":"2","key":"9106_CR43","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jacc.2010.09.024","volume":"57","author":"GY Lip","year":"2011","unstructured":"Lip GY, Frison L, Halperin JL, Lane DA. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal\/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs\/Alcohol Concomitantly) score. J Am Coll Cardiol. 2011;57(2):173-80. https:\/\/doi.org\/10.1016\/j.jacc.2010.09.024","journal-title":"J Am Coll Cardiol."},{"key":"9106_CR44","unstructured":"STROBE: Strengthening the reporting of observational studies in epidemiology https:\/\/www.strobe-statement.org\/. Accessed August 5 2024."},{"issue":"4","key":"9106_CR45","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1093\/ehjcvp\/pvaa103","volume":"7","author":"M Bo","year":"2021","unstructured":"Bo M, Corsini A, Brunetti E, Isaia G, Gibello M, Ferri N, et al. Off-label use of reduced dose direct oral factor Xa inhibitors in subjects with atrial fibrillation: a review of clinical evidence. Eur Heart J Cardiovasc Pharmacother. 2021;7(4):334-45. https:\/\/doi.org\/10.1093\/ehjcvp\/pvaa103","journal-title":"Eur Heart J Cardiovasc Pharmacother."},{"issue":"11","key":"9106_CR46","doi-asserted-by":"publisher","first-page":"e020697","DOI":"10.1161\/JAHA.120.020697","volume":"10","author":"JA Rymer","year":"2021","unstructured":"Rymer JA, Webb L, McCall D, Hills MT, Wang TY. Differences in Preferences Between Clinicians and Patients for the Use and Dosing of Direct Oral Anticoagulants for Atrial Fibrillation. J Am Heart Assoc. 2021;10(11):e020697. https:\/\/doi.org\/10.1161\/JAHA.120.020697","journal-title":"J Am Heart Assoc."},{"issue":"2","key":"9106_CR47","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1111\/bcp.15017","volume":"88","author":"S Moudallel","year":"2022","unstructured":"Moudallel S, Cornu P, Dupont A, Steurbaut S. Determinants for under- and overdosing of direct oral anticoagulants and physicians\u2019 implementation of clinical pharmacists\u2019 recommendations. Br J Clin Pharmacol. 2022;88(2):753-63. https:\/\/doi.org\/10.1111\/bcp.15017","journal-title":"Br J Clin Pharmacol."},{"issue":"3","key":"9106_CR48","doi-asserted-by":"publisher","first-page":"oeac022","DOI":"10.1093\/ehjopen\/oeac022","volume":"2","author":"J Seelig","year":"2022","unstructured":"Seelig J, Trinks-Roerdink EM, Chu G, Pisters R, Theunissen L, Trines SA, et al. Determinants of label non-adherence to non-vitamin K oral anticoagulants in patients with newly diagnosed atrial fibrillation. Eur Heart J Open. 2022;2(3):oeac022. https:\/\/doi.org\/10.1093\/ehjopen\/oeac022","journal-title":"Eur Heart J Open."},{"issue":"10","key":"9106_CR49","doi-asserted-by":"publisher","first-page":"euad302","DOI":"10.1093\/europace\/euad302","volume":"25","author":"M Guenoun","year":"2023","unstructured":"Guenoun M, Cohen S, Villaceque M, Sharareh A, Dib JC, Scwartz J, et al. Characteristics of patients with Atrial Fibrillation treated with direct oral anticoagulants and New Insights into inappropriate dosing: Results from the French National PAF Registry. Europace. 2023;25(10):euad302. https:\/\/doi.org\/10.1093\/europace\/euad302","journal-title":"Europace."},{"issue":"24","key":"9106_CR50","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1016\/j.jacc.2016.09.966","volume":"68","author":"BA Steinberg","year":"2016","unstructured":"Steinberg BA, Shrader P, Thomas L, Ansell J, Fonarow GC, Gersh BJ, et al. Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes: The ORBIT-AF II Registry. J Am Coll Cardiol. 2016;68(24):2597-604. https:\/\/doi.org\/10.1016\/j.jacc.2016.09.966","journal-title":"J Am Coll Cardiol."},{"issue":"22","key":"9106_CR51","doi-asserted-by":"publisher","first-page":"e016949","DOI":"10.1161\/JAHA.120.016949","volume":"9","author":"T Dawson","year":"2020","unstructured":"Dawson T, DeCamillo D, Kong X, Shensky B, Kaatz S, Krol GD, et al. Correcting Inappropriate Prescribing of Direct Oral Anticoagulants: A Population Health Approach. J Am Heart Assoc. 2020;9(22):e016949. https:\/\/doi.org\/10.1161\/JAHA.120.016949","journal-title":"J Am Heart Assoc."},{"issue":"4","key":"9106_CR52","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1007\/s11239-023-02880-0","volume":"56","author":"AS Wilson","year":"2023","unstructured":"Wilson AS, Triller DM, Allen A, Burnett A, Gouveia-Pisano JA, Brenner A, et al. Digital dashboards for oral anticoagulation management: a literature scoping review. J Thromb Thrombolysis. 2023;56(4):568-77. https:\/\/doi.org\/10.1007\/s11239-023-02880-0","journal-title":"J Thromb Thrombolysis."}],"container-title":["Journal of General Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-024-09106-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11606-024-09106-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-024-09106-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T16:50:58Z","timestamp":1742230258000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11606-024-09106-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,18]]},"references-count":52,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["9106"],"URL":"https:\/\/doi.org\/10.1007\/s11606-024-09106-w","relation":{},"ISSN":["0884-8734","1525-1497"],"issn-type":[{"value":"0884-8734","type":"print"},{"value":"1525-1497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,18]]},"assertion":[{"value":"21 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations:"}},{"value":"Bonnie DeLor, Jon Glover, Timothy J. Hartman, Laura Manzey, Mohammad Ateya, Katie Taylor, Ann Parks, Charles Medico, Carolyn W. Chou, Sara Hart, Rachel Bowen, Thach Trinh, Laura Duvall, and Lynette T. Davis are employees and shareholders of Pfizer Inc. Ukwen Akpoji was employed with Pfizer Inc. at the time this study was conducted. Gregory Fakelmann, Jaclynne R. Gowen, Carmen Gust, Shelby Kelsh, Shane Naylor, Jennifer Stanton, Christina Wadsworth, Eryne E. Wiethorn, William W. Wilson, and Wesley R. Zemrak report no conflicts.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest:"}}]}}